Abstract
Background: Mibefradil, a newly approved antihypertensive and antianginal drug, is the first member of a new class of calcium antagonists (CAs), the tetralol derivatives, that selectively blocks T‐type Ca2+ channels in contrast to classical CAs which, at therapeutic concentrations, block only L‐type Ca2+ channels. Since patients with chronic stable angina pectoris typically may be treated with the combination of a long‐acting nitrate and a CA, the additive efficacy and safety of mibefradil in combination with nitrate therapy needs to be determined.
Hypothesis: This study was designed to assess the efficacy, tolerability, and safety of mibefradil when added to longacting nitrate therapy in patients with chronic stable angina pectoris.
Methods: Following a 1 ‐week placebo run‐in period, patients were randomized to receive either mibefradil 50 mg (n = 96) or placebo (n = 93) once daily in addition to their nitrate therapy. After 2 weeks of active treatment, patients receiving the mibefradil were force titrated to 150 mg once daily for an additional 2 weeks. Exercise tolerance tests (ETTs) were per formed at the end of Weeks 2 and 4; patients also maintained an anginal diary during the 4‐week treatment period.
Results: After 2 weeks of treatment with 50 mg mibefradil (within the current recommended dose range), a statistically significant but modest increase in total exercise duration was observed (treatment effect 16.4 s, p = 0.04). Similarly, there was a significant increase in time to onset of ischemia (treatment effect 26 s, p = 0.008). The adverse event profile of the 50 mg dose was indistinguishable from placebo, indicating that this dose was extremely well tolerated. At Week 4, the mibefradil‐treated patients were taking 150 mg, which is above the current recommended dose range. The increase in total exercise duration was larger for the mibefradil 150 mg group than for the placebo group. For the intent‐to‐treat population, this difference did not reach statistical significance, whereas in the standard population it did (treatment effect 21 s, p = 0.05). The other two ETT variables, time to onset of angina and time to onset of 1 mm ST‐segment depression, demonstrated significantly greater effect with mibefradil 150 mg (treatment effects 40 s, p = 0.002, and 55 s, p < 0.001, respectively, for the intent‐to‐treat population). Mibefradil 150 mg was associated with more adverse events than placebo, specifically, dizziness, leg edema, and postural hypotension.
Conclusions: This study demonstrates that mibefradil 50 mg once daily in the setting of the background long‐acting nitrate therapy produces additive antianginal and anti‐ischemic effects and is extremely well tolerated.
Keywords: mibefradil, nitrate combination, angina pectoris
Full Text
The Full Text of this article is available as a PDF (746.3 KB).
References
- 1. Glasser S: Clinical mechanisms of nitrate action. Am J Cardiol 1998; 81 (1A): 49A–53A [Google Scholar]
- 2. Frishman WH: Calcium channel blockers In Cardiovascular Pharmacotherapeutics (Eds. Frishman WH, Sonnenblick EH.), p. 101–130. New York: McGraw Hill, 1997. [Google Scholar]
- 3. Frishman WH: Mibet'radil: A new selective T‐channel calcium antagonist for hypertension and angina pectoris. J Cardiovasc Pharm Therap 1997; 2: 321–330 [DOI] [PubMed] [Google Scholar]
- 4. Bernink P, Prager G, Schelling A, Kobrin I: Antihypertensiveproperties of the novel calcium antagonist mibefradil (Ro 40‐5967): A new generation of calcium antagonists'? Hypertension 1996; 27: 426–432 [DOI] [PubMed] [Google Scholar]
- 5. Bursztyn M, Kadr H, Tilvis R, Martina B, Oigman W, Talberg J, Kobrin I: Mibefradil, a novel calcium antagonist, in elderly hypertensives: Favorable hemodynamics and pharmacokinetics. Am Heart J 1997; 134: 238–247 [DOI] [PubMed] [Google Scholar]
- 6. Carney S, Wing L, Ribeiro A, Kallwellis R, Zimlichman R. Viskoper R, Mion DJ, Kobrin I: The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect. J Hum Hypertens 1997; 11: 387–393 [DOI] [PubMed] [Google Scholar]
- 7. Oparil S, Kobrin I, Abernethy D, Levine B, Reif M, Shepherd A: Dose‐response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens 1997; 10: 735–742 [DOI] [PubMed] [Google Scholar]
- 8. Alpcrt J, Kobrin I, DeQuattro V, Friedman R, Shepherd A, Fenster P: Additional anti‐anginal and anti‐ischemic efficacy of mibefradil in patients pretreated with a beta‐hlocker for chronic stable angina pectoris. Am J Cardiol 1991; 79: 1025–1030 [DOI] [PubMed] [Google Scholar]
- 9. Braun S, van der Wall E. Emanuelsson H. Kobrin I: Effects of a new calcium antagonist, mibefradil (Ro 40‐5967), on silent ischemia in patients with stable chronic angina pecloris: A multicenter placebocontrolled study. J Am Coll Cardiol 1996; 27: 317–322 [DOI] [PubMed] [Google Scholar]
- 10. Bakx A, van der Wall E, Braun S, Emanuelsson H, Bruschke A, Kobrin I: Effects of the new calcium antagonist mibefradil (Ro 405967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo‐controlled study. Am Heart J 1995; 130: 748–757 [DOI] [PubMed] [Google Scholar]
- 11. Schneeweiss A, Kobrin I, Caspi A, Marmor A, Sclarovsky S, Reisin L, Schlesinger Z: Adding the new calcium antagonist mibefradil to patients on chronic beta‐blocker therapy results in improved anti‐anginal and anti‐ischemic efficacy. Am Heart J 1998; 35: 272–280 [DOI] [PubMed] [Google Scholar]
- 12. Tzivoni D, Kadr H, Braat S, Rutsch W, Ramires J, Kobrin I: Efficacy of mibefradil in comparison to amlodipine in suppressing exercise‐induced and daily silent ischemia: Results of a multicenter, placebo‐controlled trial. Circulation 1997; 96: 2557–2564 [DOI] [PubMed] [Google Scholar]
- 13. Alpert J, Bakx A, Braun S, Frishman W, Schneeweiss A, Tzivoni D, Kobrin I: The anti‐anginal and anti‐ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris: Placebo‐controlled studies. Am J Cardiol 1997; 80: 20C–26C [DOI] [PubMed] [Google Scholar]
- 14. Davies MJ, Pathology of the conducting system In Cardiology in Old Age (Eds. Caird FL, Dalle JLC, Kennedy RD.), p. 57–59. New York: Plenum Publishing Corp., 1976. [Google Scholar]
- 15. Wei JY: Use of calcium entry blockers in elderly patients: Special considerations. Circulation 1989; 80 (suppl IV) IV‐I71–IV‐I77 [PubMed] [Google Scholar]
- 16. Rutledge A, Triggle D: The binding interactions of RO 40‐5967 at the L‐type CA2+ channel in cardiac tissue. Eur J Pharmacol 1995; 90: 155–158 [DOI] [PubMed] [Google Scholar]
- 17. Mishra S, Hermsmeyer K: Selective inhibition of T‐type Ca2+ channels by RO40‐5967. Circ Res 1994; 75: 144–148 [DOI] [PubMed] [Google Scholar]
- 18. Katz A: Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol 1996; 28: 522–529 [DOI] [PubMed] [Google Scholar]
- 19. Rousseau M, Hayashida W, van Eyll C, Hess O, Benedict C, Ahn S, Chapella F, Kobrin I, Pouleur H: Hemodynamic and cardiac effects of the selective T‐type and L‐type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol 1996; 28: 972–979 [DOI] [PubMed] [Google Scholar]
- 20. Onto K, Satoh K, Taira N: Cardiovascular profile of RO 40‐5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood perfused dog hearts. J Cardiovasc Pharmacol 1993; 22: 293–299 [DOI] [PubMed] [Google Scholar]
- 21. Schmitt R, Kleinbloesem C, Belz G, Schroeter V, Feifel U, Pozenel H, Kirch W, Halabi A, Woittiez A‐J, Welker H, van Brummelen P: Hemodynamic and humoral effects of the novel calcium antagonist RO 40‐5967 in patients with hypertension. Clin Pharmacol Ther 1992; 52: 314–323 [DOI] [PubMed] [Google Scholar]